Obstructive sleep apnoea as a risk factor for atherosclerosis - implication for preventive and personalised treatment.
Obstructive sleep apnoea as a risk factor for atherosclerosis - implication for preventive and personalised treatment.
复制标题
DOI：
10.1007/s13167-011-0070-5
复制
发表时间：
2011-03
期刊：
影响因子：
6.5
通讯作者：
Skowasch, Dirk
中科院分区：
文献类型：
--
作者：
Tuleta, Izabela;Pabst, Stefan;Juergens, Uwe R;Nickenig, Georg;Skowasch, Dirk
动脉粥样硬化及其表现和相关疾病是工业国家发病率和死亡率的主要原因。动脉粥样硬化的病理机制是复杂的，包括外源性因素和遗传易感性。除了明确的动脉粥样硬化发生的危险因素外，阻塞性睡眠呼吸暂停（OSA）也越来越受到重视。越来越多的证据表明阻塞性睡眠呼吸暂停与血管病变有关。虽然确切机制尚不清楚，但OSA典型的间歇性缺氧可导致氧化应激、炎症、代谢和神经变化，从而导致动脉粥样硬化基础上的血管功能障碍。已经证明持续气道正压通气（CPAP）治疗具有血管保护作用。本文综述了流行病学和临床研究的数据，重点介绍了OSA与动脉粥样硬化之间的可能机制、有助于识别心血管高危OSA患者的预测性生物标志物和个性化治疗方法。
Atherosclerosis with its manifestations and associated diseases is a main cause of morbidity and mortality in industrial countries. The pathomechanisms underlying atherosclerosis are complex and comprise exogenous factors as well as genetic predisposition. Beyond the well-defined risk factors for the development of atherosclerosis, obstructive sleep apnoea (OSA) merits more and more attention. A growing body of evidence has associated OSA with vascular pathologies. Although the exact mechanisms involved are not known, the occurrence of intermittent hypoxia typical for OSA may lead to oxidative stress, inflammation, metabolic and neural changes which in turn are responsible for vessel dysfunction underlying atherosclerosis. It has been demonstrated that therapy with continuous positive airway pressure (CPAP) plays a vasoprotective role. This review summarises data resulting from epidemiological and clinical studies with emphasis on the possible mechanisms linking OSA with atherosclerosis, predictive biomarkers helping identify OSA patients at high cardiovascular risk and personalised treatment approaches.